Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Caisse DE Depot ET Placement DU Quebec

Caisse DE Depot ET Placement DU Quebec decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 31.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 234,589 shares of the medical research company’s stock after selling 109,479 shares during the period. Caisse DE Depot ET Placement DU Quebec’s holdings in Thermo Fisher Scientific were worth $122,040,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Barrett & Company Inc. purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at about $28,000. FPC Investment Advisory Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $28,000. Pillar Financial Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $29,000. Missouri Trust & Investment Co acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at $29,000. Finally, Endeavor Private Wealth Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at $30,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the sale, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,200 shares of company stock worth $13,235,041 over the last ninety days. Company insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on TMO shares. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Wednesday, April 23rd. Robert W. Baird reduced their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Scotiabank decreased their target price on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating for the company in a research report on Friday, April 25th. Evercore ISI decreased their price objective on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating for the company in a report on Thursday, April 24th. Finally, Royal Bank of Canada dropped their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $607.43.

Thermo Fisher Scientific Trading Up 0.2 %

TMO stock opened at $428.48 on Thursday. The company has a market capitalization of $161.75 billion, a PE ratio of 25.92, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific Inc. has a one year low of $409.85 and a one year high of $627.88. The company’s 50 day moving average price is $480.79 and its two-hundred day moving average price is $524.13. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter last year, the firm earned $5.11 earnings per share. The business’s revenue for the quarter was up .2% on a year-over-year basis. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were paid a $0.43 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. Thermo Fisher Scientific’s dividend payout ratio is 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.